[Compliance, efficacy and tolerability of the therapeutic regimen recommended by National Consensus on Tuberculosis]

Enferm Infecc Microbiol Clin. 1997 Mar;15(3):129-33.
[Article in Spanish]

Abstract

Background: To study the degree of adhesion, efficacy, and tolerance of therapeutic guidelines advocated by the National Consensus on tuberculosis.

Methods: A prospective study of a cohort of 84 patients receiving a diagnosis of tuberculosis in a Basic General Health Area between 1-3-1993 and 28-2-1994 treated with the regimen recommended by the National Council. The patients were evaluated clinically and microbiologically during the treatment and during twelve months follow-up.

Results: Fifty-two patients (61.9%) were male and 32 (38.1%) female, aged 29.9 +/- 19.7 years (r = 1-84 years). Seventy-four (88.1%) were index cases and 10 (11.4%) household contacts. Eight patients (9.5%) were also infected with HIV, 71 (84.5%) presented pulmonary tuberculosis and 13 (15.5%) extrapulmonary forms. Therapeutic compliance was correct in 80 cases (95.2%) and incorrect in 4 (4.8%). It was well-tolerated in 73 patients (91.2%), there was slight toxicity in five (6.3%) and severe in two (2.5%). Seventy-four patients (88.1%) were cured, there was one therapeutic failure (1.2%) and five relapses (6%). Overall mortality was 4.8% and attributable mortality 1.2%.

Conclusion: Our results seem to confirm a high degree of adhesion, good tolerance and acceptable therapeutic efficacy of the scheme proposed by the National Council.

Publication types

  • Clinical Trial
  • English Abstract
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents*
  • Antitubercular Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Drug Therapy, Combination / therapeutic use*
  • Female
  • HIV Infections / complications
  • Humans
  • Infant
  • Isoniazid / therapeutic use*
  • Male
  • Middle Aged
  • Patient Compliance
  • Prospective Studies
  • Pyrazinamide / therapeutic use*
  • Recurrence
  • Rifampin / therapeutic use*
  • Tuberculosis / complications
  • Tuberculosis / drug therapy*
  • Tuberculosis / mortality
  • Tuberculosis, Multidrug-Resistant / complications
  • Tuberculosis, Multidrug-Resistant / drug therapy
  • Tuberculosis, Multidrug-Resistant / epidemiology

Substances

  • Anti-Bacterial Agents
  • Antitubercular Agents
  • Pyrazinamide
  • Isoniazid
  • Rifampin